Faculty Collaboration Database

Central Neuromodulators for Treating Functional GI Disorders: A Primer. Am J Gastroenterol 2017 May;112(5):693-702

Date

03/30/2017

Pubmed ID

28349992

DOI

10.1038/ajg.2017.57

Scopus ID

2-s2.0-85016095445 (requires institutional sign-in at Scopus site)   38 Citations

Abstract

Patients with functional GI disorders (FGIDs) are commonplace in the gastroenterologist's practice. A number of these patients may be refractory to peripherally acting agents, yet respond to central neuromodulators. There are benefits and potential adverse effects to using TCAs, SSRIs, SNRIs, atypical antipsychotics, and miscellaneous central neuromodulators in these patients. These agents can benefit mood, pain, diarrhea, constipation, nausea, sleep, and depression. The mechanisms by which they work, the differences between classes and individual agents, and the various adverse effects are outlined. Dosing, augmentation strategies, and treatment scenarios specifically for painful FGIDs, FD with PDS, and chronic nausea and vomiting syndrome are outlined.

Author List

Sobin WH, Heinrich TW, Drossman DA

Authors

Thomas W. Heinrich MD Professor in the Psychiatry and Behavioral Medicine department at Medical College of Wisconsin
W Harley H. Sobin MD Adjunct Assistant Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Antidepressive Agents, Tricyclic
Antipsychotic Agents
Clinical Competence
Defecation
Gastrointestinal Diseases
Gastrointestinal Hemorrhage
Humans
Nausea
Neurotransmitter Agents
Serotonin Syndrome
Serotonin and Noradrenaline Reuptake Inhibitors
Sexual Dysfunction, Physiological
Vomiting